Review on Anaplastic large cell lymphoma, ALKnegative, with data on clinics, and the genes involved.
Pathology
By definition, the morphologic appearance is similar to that seen in ALCL, ALK-positive (Mason, Harris et al. 2008) . Specifically, most cases resemble the so-called "common" pattern of ALK, ALK-positive and show sheet-like growth of tumor cells, sometimes sparing residual lymphoid follicles (Delsol, Falini et al. 2008 ). Sinusoidal involvement is common, and cohesive clusters of intrasinusoidal tumor cells may mimic metastatic carcinoma. The tumor cells typically are large and may show significant pleomorphism. So-called "hallmark" cells, with horseshoe-shaped or reniform nuclei, always can be identified (Benharroch, MeguerianBedoyan et al. 1998) . Immunophenotyping studies are essential to the diagnosis of ALCL, ALKnegative. All cases express CD30 by definition. Aberrant loss of pan-T-cell antigen expression is common, and about two-thirds of cases express cytotoxic proteins (TIA1, granzyme B, or perforin) (Savage, Harris et al. 2008 ). ALK protein is absent.
Treatment
ALCL, ALK-negative is typically treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like chemotherapy, often followed by autologous stem cell transplantation (Bennani-Baiti, Ansell et al. 2016) . New targeted agents such as brentuximab vedotin and histone deacetylase inhibitors have demonstrated efficacy in relapsed and refractory disease.
Prognosis
The prognosis for ALCL, ALK-negative is poorer than for ALCL, ALK-positive, with a 5-year overall survival (OS) rate of 49% compared to 70% for the latter (Savage, Harris et al. 2008) . However, prognosis is better than for most other types of T-cell non-Hodgkin lymphomas, including peripheral Tcell lymphoma, not otherwise specified (PTCL, NOS). Recent data have shown that ALCL, ALKnegative is a genetically heterogeneous disease, and that outcomes vary widely based on genetic subtype (Parrilla Castellar, Jaffe et al. 2014). Specifically, 5-year OS was very good (90%) in patients carrying DUSP22 rearrangements, poor (17%) in TP63/ -rearranged cases, and intermediate (42%) in patients lacking ALK/, DUSP22, and TP63 rearrangements.
Genetics
Recurrent somatic mutations in the JAK1/ and/or STAT3/ genes have been reported in 18% of ALCL, ALK-negative (Crescenzo, Abate et al. 2015) . JAK1 mutations were most commonly G1097D/S, while STAT3 mutations included Y640F, N647I, D661Y, and A662V.
Cytogenetics

Cytogenetics morphological
Copy number losses involving PRDM1 (6q21) and/or TP53/ (17p13) are recurrent in ALCL, ALKnegative, and have been associated with poor survival (Boi, Rinaldi et al. 2013) . Recurrent chromosomal rearrangements involving the DUSP22 -IRF4/ locus on 6p25.3 are present in ~30% of ALCL, ALK-negative (Feldman, Law et al. 2009; Feldman, Dogan et al. 2011; Parrilla Castellar, Jaffe et al. 2014) . The most common partner is a non-genic region on 7q32.3. DUSP22 rearrangements are associated with decreased expression of the dual-specificity phosphatase gene, DUSP22; lack of cytotoxic marker expression; favorable prognosis; and distinct morphologic features (King, Dao et al. 2016) . Rearrangements involving TP63, most often partnering with TBL1XR1/ occur in ~8% of ALCL, ALK-negative and have been associated with poor prognosis (Vasmatzis, Johnson et al. 2012; Parrilla Castellar, Jaffe et al. 2014 ).
Gene fusions involving tyrosine kinase genes other than ALK have been reported in ALCL, ALKnegative, including TYK2 (t(10;19)(q24;p13) (NFKB2/TYK2), t(1;19)(p34;p13) (PABPC4/TYK2) and ROS1 (t(6;10)(q22;q24) (NFKB2/ROS1), (NCOR2/ROS1) (Crescenzo, Abate et al. 2015) .
